Fundraising Fox
Edgewise Therapeutics
NASDAQ: EWTXBoulder, US · Founded 2017 · 144 employees on LinkedIn · 8 known investors
Find your way into Edgewise Therapeutics
Sign up to see every warm intro you have to Edgewise Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Edgewise Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Edgewise Therapeutics discovers and develops small molecule medicines targeting muscle proteins to treat neuromuscular and cardiac diseases, including sevasemten for muscular dystrophies and EDG-7500 for cardiomyopathy, leveraging a proprietary drug discovery platform based on muscle physiology and high-throughput functional assays.
Founders & leadership
Edgewise Therapeutics was founded in 2017 by Kevin Koch, Alan Russell, and Badreddin Edris.
Board
Investors · 8
How we know: Foresite Capital's portfolio page · Not right? Tell us
How we know: OrbiMed's portfolio page · the S-1 prospectus · the VCSheet dataset · Not right? Tell us
How we know: US Venture Partners's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Viking Global's portfolio page · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$120.1M disclosed across 2 rounds · 2019–2020
▶$95MraisedDec 2020 · 21 investors · BiotechnologyRule 506(b)
- Kevin KochExecutive Officer, Director
- Peter ThompsonDirector
- Kenneth HarrisonDirector
- Jonathan RootDirector
- Alan RussellDirector
- Offering amount
- $95M
- Amount sold
- $95M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$25.1MraisedSep 2019 · 6 investors · Other TechnologyRule 506(b)
- Kevin KochExecutive Officer, Director
- Peter ThompsonDirector
- Kenneth HarrisonDirector
- Jonathan RootDirector
- Alan RussellDirector
- Offering amount
- $50.1M
- Amount sold
- $25.1M
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
3 people who came through Edgewise Therapeutics went on to found or lead other companies.
Frequently asked questions
- What does Edgewise Therapeutics do?
- Edgewise Therapeutics discovers and develops small molecule medicines targeting muscle proteins to treat neuromuscular and cardiac diseases, including sevasemten for muscular dystrophies and EDG-7500 for cardiomyopathy, leveraging a proprietary drug discovery platform based on muscle physiology and high-throughput functional assays.
- Who founded Edgewise Therapeutics?
- Edgewise Therapeutics was founded by Kevin Koch, Alan Russell, Badreddin Edris in 2017.
- Who are Edgewise Therapeutics's investors?
- Edgewise Therapeutics's investors include Boulder Ventures, Foresite Capital, OrbiMed, US Venture Partners, Viking Global, Wellington Management, Deerfield Management Company, Novo Holdings.
- How much funding has Edgewise Therapeutics raised?
- Edgewise Therapeutics has disclosed $120.1M raised across 2 rounds.
- Where is Edgewise Therapeutics headquartered?
- Edgewise Therapeutics is headquartered in Boulder, US.